Johnson Matthey receives two pharmaceutical and biotech CMO Leaderships Awards in 2015

Published: 19-Mar-2015
Manufacturing Pharmaceutical

The awards are presented to companies achieving top ranking against various criteria and for specific industry segments


Johnson Matthey, a leading provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has been recognised in the 2015 CMO Leadership Awards for the Reliability and Regulatory Track record of its Pharma Services to the Biotech Industry.

The CMO Leadership Awards are presented by Life Science Leader Magazine and based upon extensive industry research conducted by Nice Insight, surveying thousands of industry executives from multiple industry segments across the globe.

The awards are presented to companies achieving top ranking against various criteria and for specific industry segments. Johnson Matthey was awarded in the two following categories:

  • Reliability for Emerging Biotech Companies
  • Regulatory Track Record for Biotech Companies

Commenting on the awards, Bernhard Paul, General Manager of Johnson Matthey Pharma Services, said: 'We are honoured to be recognised with the CMO Leadership Awards for Reliability and Regulatory track record. This is a testament to our culture of continuous improvement, customer focus, and our commitment to quality. Our team at Johnson Matthey Pharmaceutical Materials and Services focuses on creating value for our customers and providing them with the highest quality products and services.'

  • Companies:
  • Thats Nice
  • Johnson Matthey
See more

You may also like

Manufacturing

The US pharmaceutical landscape: growth, innovation and challenges ahead

Read more
The US pharmaceutical market is one of the largest in the world and is experiencing healthy growth owing to its ageing population, the willingness of consumers to spend on healthcare and a high level of investment in R&D, the results of which receive strong intellectual property protection

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    How CDMOs can set a new gold standard when it comes to going green Sustainability is more than a feel-good initiative or a choice; it’s a strategic imperative. Not missing a beat, pharma companies have been making a concerted effort towards positive change, reports Tim Lowery, President of JSR Life Sciences and CEO, KBI Biopharma
  2. Mastering modified-release performance: excipient considerations Imagine a world where enhanced therapeutic efficacy, improved patient compliance and reduced adverse effects are tangible outcomes — even for drugs with short pharmacokinetic (PK) half-lives or narrow therapeutic indices. This is becoming a reality with modified-release (MR) oral delivery systems such as hydrophilic matrix tablets
  3. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence
  4. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

The US pharmaceutical landscape: growth, innovation and challenges ahead

The US pharmaceutical market is one of the largest in the world and is experiencing healthy growth owing to its ageing population, the willingness of consumers to spend on healthcare and a high level of investment in R&D, the results of which receive strong intellectual property protection
Manufacturing

JM Health rebrands as Veranova following sale to Altaris Capital Partners

Veranova, formerly known as Johnson Matthey Health, has launched as an independent company following the acquisition by Altaris Capital Partners, LLC from Johnson Matthey PLC
Manufacturing

Scorpion Biological Services announces new Kansas commercial biomanufacturing facility

Biopharmaceutical contract development and manufacturing organisation Scorpion Biological Services announced a planned development partnership with a private developer, the State of Kansas, and local and university affiliates
Manufacturing

Johnson Matthey signs long-term supply agreement

The supply deal has been signed to support RNA-based programmes to treat Duchenne muscular dystrophy
Pharmaceutical

Johnson Matthey and Immunomedics join forces on cancer treatment

A strategic manufacturing partnership has been announced for key ingredient of FDA priority review candidate
Manufacturing

JM to offer a new process to synthesise CBD

Johnson Matthey to offer a new process to synthesise ultra-pure cannabidiol, expanding on existing cannabinoid offerings
Media

Slow and steady

Generic drugs find a growing position in the US pharma market
Subscribe now